Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...

Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

Researchers at Massachusetts General Hospital have discovered that meeting the weekly recommended physical activity levels, ...

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

April Barnes dreamed of owning her own eatery since she was 16, working her first job at a King’s restaurant in Plum. “I ...

Davis-based biological controls company Invasive Species Corp., founded by biologics pioneer Pam Marrone, has taken office ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...

Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua ...